Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.68B | $1.86B | $2.27B | $2.62B | $2.92B | $3.54B | $3.98B | $4.13B | $4.05B | $4.02B |
| Revenue growth | — | 10.5% | 22.0% | 15.7% | 11.5% | 21.1% | 12.3% | 3.9% | -1.9% | -0.9% |
| Operating income | $238M | $288M | $331M | $351M | $433M | $590M | $651M | $617M | $227M | $25.2M |
| Operating margin | 14.1% | 15.5% | 14.6% | 13.4% | 14.8% | 16.7% | 16.4% | 14.9% | 5.6% | 0.6% |
| Net income | $155M | $123M | $226M | $252M | $364M | $391M | $486M | $475M | $22.2M | -$144M |
| Net margin | 9.2% | 6.6% | 10.0% | 9.6% | 12.5% | 11.0% | 12.2% | 11.5% | 0.5% | -3.6% |
| EPS (diluted) | $3.23 | $2.54 | $4.62 | $5.07 | $7.20 | $7.60 | $9.48 | $9.22 | $0.20 | -$2.91 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $317M | $318M | $441M | $481M | $547M | $761M | $620M | $684M | $735M | $738M |
| Capital expenditures | $55.3M | $82.4M | $140M | $141M | $167M | $229M | $325M | $319M | $233M | $219M |
| Free cash flow | $262M | $236M | $301M | $340M | $380M | $532M | $295M | $365M | $502M | $518M |
| Share buybacks | $12.3M | $107M | $13.8M | $18.1M | $24.0M | $40.7M | $38.7M | $24.2M | $119M | $361M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $118M | $164M | $195M | $238M | $228M | $241M | $234M | $277M | $195M | $214M |
| Total assets | $2.71B | $2.93B | $3.86B | $4.69B | $5.49B | $7.02B | $7.60B | $8.20B | $7.53B | $7.14B |
| Total liabilities | $1.86B | $1.87B | $2.52B | $3.03B | $3.35B | $4.43B | $4.58B | $4.54B | $4.02B | $3.92B |
| Long-term debt | $1.19B | $1.09B | $1.63B | — | — | — | — | — | — | — |
| Shareholders' equity | $837M | $1.05B | $1.32B | $1.63B | $2.11B | $2.53B | $2.98B | $3.60B | $3.46B | $3.16B |
| Retained earnings | $165M | $289M | $42.1M | $280M | $625M | $981M | $1.43B | $1.89B | $1.81B | $1.39B |
| Shares (wtd avg diluted) | 48.0M | 48.6M | 49.0M | 49.7M | 50.6M | 51.4M | 51.3M | 51.5M | 51.6M | 49.6M |
Every figure is extracted from CHARLES RIVER LABORATORIES INTERNATIONAL, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.